Analysis |

Moderna's COVID Vaccine Progress Is Good News, but Israel's Not Out of the Woods Yet

In theory, the Moderna contract should have been much more balanced and reasonable than the Pfizer deal, but this isn’t quite the case

Meirav Arlosoroff
Meirav Arlosoroff
Send in e-mailSend in e-mail
A sign marks the headquarters of Moderna Therapeutics, which is developing a vaccine against the coronavirus disease (COVID-19), in Cambridge, Massachusetts, U.S., May 18, 2020
A sign marks the headquarters of Moderna Therapeutics, which is developing a vaccine against the coronavirus disease (COVID-19), in Cambridge, Massachusetts, U.S., May 18, 2020 Credit: REUTERS/Brian Snyder